Gilead–PepStar: program acquisition closes
Gilead’s October 29 release describes a definitive agreement for PepStar’s oral IL-23R program, including Phase 1 HCXT-2001, subject to closing conditions. This is an identified drug-program transaction.
Gilead Sciences / GILDPublic biotechM&ADate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
Primary evidence
Reporting date unconfirmed — research candidate
Gilead Q3 2026 results and transaction updatePublished 2026-10-29
Potential outcome market
Will Gilead complete its announced acquisition of PepStar’s oral IL-23R inhibitor program?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.